pubmed.ncbi.nlm.nih.gov

Antidepressant effects of ketamine in depressed patients - PubMed

️Sat Jan 01 2000

Clinical Trial

Antidepressant effects of ketamine in depressed patients

R M Berman et al. Biol Psychiatry. 2000.

Abstract

Background: A growing body of preclinical research suggests that brain glutamate systems may be involved in the pathophysiology of major depression and the mechanism of action of antidepressants. This is the first placebo-controlled, double-blinded trial to assess the treatment effects of a single dose of an N-methyl-D-aspartate (NMDA) receptor antagonist in patients with depression.

Methods: Seven subjects with major depression completed 2 test days that involved intravenous treatment with ketamine hydrochloride (.5 mg/kg) or saline solutions under randomized, double-blind conditions.

Results: Subjects with depression evidenced significant improvement in depressive symptoms within 72 hours after ketamine but not placebo infusion (i.e., mean 25-item Hamilton Depression Rating Scale scores decreased by 14 +/- SD 10 points vs. 0 +/- 12 points, respectively during active and sham treatment).

Conclusions: These results suggest a potential role for NMDA receptor-modulating drugs in the treatment of depression.

PubMed Disclaimer

Comment in

Commentary [the mood in the field of antidepressant drug discovery].
Witkin JM. Witkin JM. CNS Neurol Disord Drug Targets. 2011 Nov;10(7):762-3. doi: 10.2174/187152711798072338. CNS Neurol Disord Drug Targets. 2011. PMID: 21999728 No abstract available.
Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: a case report.
Gálvez V, O'Keefe E, Cotiga L, Leyden J, Harper S, Glue P, Mitchell PB, Somogyi AA, DeLory A, Loo CK. Gálvez V, et al. Biol Psychiatry. 2014 Aug 1;76(3):e1-2. doi: 10.1016/j.biopsych.2013.12.010. Epub 2014 Jan 3. Biol Psychiatry. 2014. PMID: 24507509 No abstract available.

Dataset use reported in

Ketamine's antidepressant action: beyond NMDA receptor inhibition.
Hashimoto K. Hashimoto K. Expert Opin Ther Targets. 2016 Nov;20(11):1389-1392. doi: 10.1080/14728222.2016.1238899. Epub 2016 Sep 28. Expert Opin Ther Targets. 2016. PMID: 27646666

Cited by

Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
Henter ID, Park LT, Zarate CA Jr. Henter ID, et al. CNS Drugs. 2021 May;35(5):527-543. doi: 10.1007/s40263-021-00816-x. Epub 2021 Apr 26. CNS Drugs. 2021. PMID: 33904154 Free PMC article. Review.
Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Furey ML, Zarate CA Jr. Niciu MJ, et al. Int J Neuropsychopharmacol. 2014 Oct 31;18(1):pyu039. doi: 10.1093/ijnp/pyu039. Int J Neuropsychopharmacol. 2014. PMID: 25539512 Free PMC article. Clinical Trial.
Rapid-acting antidepressant drugs modulate affective bias in rats.
Hinchcliffe JK, Stuart SA, Wood CM, Bartlett J, Kamenish K, Arban R, Thomas CW, Selimbeyoglu A, Hurley S, Hengerer B, Gilmour G, Robinson ESJ. Hinchcliffe JK, et al. Sci Transl Med. 2024 Jan 10;16(729):eadi2403. doi: 10.1126/scitranslmed.adi2403. Epub 2024 Jan 10. Sci Transl Med. 2024. PMID: 38198569 Free PMC article.
Ketamine Corrects Stress-Induced Cognitive Dysfunction through JAK2/STAT3 Signaling in the Orbitofrontal Cortex.
Patton MS, Lodge DJ, Morilak DA, Girotti M. Patton MS, et al. Neuropsychopharmacology. 2017 May;42(6):1220-1230. doi: 10.1038/npp.2016.236. Epub 2016 Oct 17. Neuropsychopharmacology. 2017. PMID: 27748739 Free PMC article.
Depression: Ketamine steps out of the darkness.
Malinow R. Malinow R. Nature. 2016 May 26;533(7604):477-8. doi: 10.1038/nature17897. Epub 2016 May 4. Nature. 2016. PMID: 27144350 Free PMC article.

Antidepressant effects of ketamine in depressed patients - PubMed